Non-alcoholic fatty liver disease: comparative assessment of diagnostic and treatment approaches in the Russian Federation and People’s Republic of China by M. Ch. Semenistaya, Fan Jian-Gao, O. B. Velichenko, Ye. A. Kuznetsova, Ch. S. Pavlov

“…According to the international clinical guidelines, NAFLD screening methods should include elastometry and serological tests to rule out severe liver fibrosis (F> 2). Liver biopsy is carried out at contradictory data of liver elastometry and serological fibrosis markers. …”
Get full text

Combination of autoimmune hepatitis to non-alcoholic steatohepatitis (Clinical case) by A. A. Driga, M. V. Mayevskaya, V. T. Ivashkin

“…Liver biopsy was repeated: HAI was 10 points (3+1+3+3), hydropic, small and large droplet fatty dystrophy, moderate fibrosis. Clinical diagnosis was following: AIH of 1-st type with high degree of activity, NASH with severe fibrosis, second type DM in compensated phase, morbid obesity, dyslipidemia, systemic hypertension («metabolic syndrome»). …”
Get full text

Two faces of the same coin non alcoholic fatty liver disease; with and without diabetes: Comparative clinico pathological analysis: A cross sectional observational study by Syed Mushfiq, Ghulam Nabi Yatoo, Bilal Ahmad Mir, Zubaida Rasool

“…The histological grade of steatosis and fibrosis as depicted by the mean NAS score (5.7 ± 1.2 vs 4.63 ± 0.8) was higher in diabetic NAFLD vs non-diabetic NAFLD; however, only the fibrosis stage was statistically significant between the groups (P < 0.001). …”
Get full text

Cell autonomous TLR4 signaling modulates TGF-β induced activation of human cardiac fibroblasts by Gayathri Vijayakumar, Anisha Latha, Aiswaria P. Anil, Yogini Surve, Aiswarya R, Bipin G. Nair, Indulekha CL. Pillai

“…Fibrosis is one of the major outcomes following injury in the heart. …”
Get full text

The theses for PhD degree by article Editorial

“…Ch.S. Pavlov – Liver fibrosis at chronic viral hepatitis B and C.…”
Get full text

Pancreas Proapoptotic Proteases in Patients with Chronic Pancreatitis by N. B. Gubegritz, E. A. Krylova, Yu. A. Gaidar

“…No significant differences were observed with regard to the severity and frequency of fibrosis of various degrees in the groups: mild, moderate, severe and full fibrosis was detected in 6.7 %, 20.0 %, 16.7 % and 56.6 %, respectively. …”
Get full text

Safety and efficacy of telaprevir in treatment of a chronic hepatitis C in patients of the Russian population included in early access program study by D. T. Abrurakhmanov, V. G. Morozov, I. G. Nikitin, P. O. Bogomolov, N. I. Geyvandova, Ye. N. Bessonova, I. G. Bakulin, V. A. Isakov, K. V. Zhdanov, M. V. Mayevskaya, Ye. A. Nurmukhametova, E. Z. Burnevich, Ye. V. Chesnokov, V. D. Pasechnikov, A. Hill, I. Lonjon-Domanec, S. N. Kizhlo

“…HEP3002 is the international early access program of efficacy and safety estimation of telaprevir in combination to peginterferon alpha and ribavirin for patients with severe fibrosis or liver cirrhosis caused by hepatitis C virus (HCV) genotype 1. …”
Get full text

Follistatin like-1 aggravates silica-induced mouse lung injury by Yinshan Fang, Si Zhang, Xiaohe Li, Fangxin Jiang, Qiao Ye, Wen Ning

“…Meanwhile, Fstl1 promoted fibrosis via positive regulation of TGF-β1 signaling. …”
Get full text

Ocular manifestations and treatment safety in hepatitis C patients undergoing direct-acting antiviral therapy: a prospective cohort study by Guilherme Thomé de Carvalho, Carlos Eduardo Brandão Mello, Kelma Macedo Pohlmann Simões, Mário Martins dos Santos Motta, Max Kopti Fakoury, Bruno Vasconcelos Coimbra, Laura Gomes Nunes Melo, Flávio Mac Cord Medina

“…All patients achieved sustained virological response, and a notable improvement in fibrosis degree post-treatment was observed. No ocular complications attributable to direct-acting antiviral therapy were reported during the study. …”
Get full text

Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER st... by M. V. Mayevskaya, V. T. Ivashkin, O. O. Znoyko, Ye. A. Klimova, D. T. Abdurakhmanov, I. G. Bakulin, P. O. Bogomolov, E. Z. Burnevich, M. Yu. Galushko, N. I. Geyvandova, K. V. Zhdanov, Ye. V. Esaulenko, S. N. Kizhlo, D. Yu. Konstantinov, N. I. Mironova, V. G. Morozov, Ye. A. Strebkova, I. G. Nikitin, M. F. Osipenko, V. D. Pasechnikov, O. I. Sagalova, I. M. Khayertynova, V. P. Chulanov, A. A. Yakovlev, I. A. Vasyutin, Ye. P. Tarkhova, E. N. Krasavina, M. Yu. Samsonov

“…In treatment-naïve patients from the main group SVR24 was achieved in 90.8% at initial METAVIR F0-F2 liver fibrosis stage and in 75% at F3 liver fibrosis stage. …”
Get full text

Application of ursodeoxycholic acid at non-alcoholic and alcohol-induced steatohepatitis by Ye. A. Fedos’ina, M. V. Mayevskaya

“…In the case of NASH itself on a background of obesity UDCA can be prescribed as a drug with cytoprotective, antiapoptotic action, retarding fibrosis.…”
Get full text

Economic Evaluation of Boceprevir for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus Infection in Hungary by Raymond Odhiambo, Jagpreet Chhatwal, Shannon Allen Ferrante, Antoine El Khoury, Elamin Elbasha

“…**Methods:** A Markov model was developed to evaluate the long-term clinical benefits and the costeffectiveness of the triple therapy from the Hungarian payer perspective. Model states were fibrosis (F0–F4, defined using METAVIR fibrosis scores), decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), liver transplantation (LT), and liver-related deaths (LD). …”
Get full text

Efficacy and safety of glycyrrhizic acid combined to essential phospholipids (Phosphogliv) at non-alcoholic fatty liver disease: results of multicenter double blind randomized plac... by V. T. Ivashkin, I. G. Bakulin, P. O. Bogomolov, M. V. Matsiyevich, N. I. Geyvandova, P. V. Koroy, S. V. Nedogoda, O. A. Sablin, L. G. Lenskaya, Ye. V. Beloborodova, A. A. Bagretsova, R. A. Abdulkhakov, M. F. Osipenko, I. V. Osipova, D. A. Pocheptsov, Ye. V. Chumachek, O. M. Khromtsova, Ye. V. Kuzmicheva

“…Serum levels of inflammatory marker adiponectin, NAFLD fibrosis score, treatment effect on quality of life and safety of patients were monitored. …”
Get full text

A comprehensive analysis of percutaneous liver biopsy characteristics and pathological manifestations in a large patient cohort (2009–2024) by Minling Cao, Jiayi Zeng, Jiayu Wang, Junmin Jiang

“…Patients with hepatitis B complicated by MASLD exhibited disease exacerbation in middle age, with both liver inflammation and fibrosis grading worsening as age advanced. Furthermore, within the same age bracket, the severity of inflammation and the extent of fibrosis were more pronounced in cases where chronic hepatitis B was combined with MASLD compared to those with isolated chronic hepatitis B or MASLD. …”
Get full text

Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion by V. V. Tsukanov, M. F. Osipenko, E. V. Beloborodova, M. A. Livzan, I. B. Khlynov, S. A. Alekseenko, Yu. P. Sivolap, J. L. Tonkikh, A. V. Vasyutin

“…For the diagnosis of liver pathology, it is important to determine the stage of fibrosis and the severity of the exacerbation of the disease. …”
Get full text

A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline by Amit Garg, Jun Xu, Mario Fioravanti, Taku Nakashima

“…None of the studies included in this systematic review reported any incidence of fibrosis or ergotism with nicergoline.…”
Get full text

Methods of risk prediction and monitoring of treatment response rate of bleedings from esophageal varices in patients with liver cirrhosis by D. V. Garbuzenko

“…Their inherent disadvantages promoted studying of sensitivity and specificity of other predictors of this complication, as well as technologies estimating severity of portal hypertension, such as capsule endoscopy, Doppler ultrasound, multispiral computer tomography, non-invasive methods of liver fibrosis diagnostics and of some others.Conclusion. …”
Get full text

CALLY index, but not HALP score, is associated with mortality in cirrhosis patients by Yıldız Günay, Bedel Cihan, Zortuk Ökkeş, Selvi Fatih, Karanci Yusuf

“…Cirrhosis is a chronic liver disease that is characterized by inflammation and fibrosis, as well as liver dysfunction. The CALLY index and HALP score have recently provided crucial data in the diagnosis, follow-up, and prognosis of numerous diseases, particularly those of a malignant nature and those affecting the gastrointestinal system. …”
Get full text

Meconium Peritonitis and Periorchitis: Report of a Prenatal Case by Cem Yaşar Sanhal, İnanç Mendilcioğlu, Adnan Aslan, Murat Özekinci, Mehmet Şimşek

“…Meconium peritonitis may also be caused by viral infections (cytomegalovirus or parvovirus B19) and cystic fibrosis. Here, we report of a patient with fetal meconium peritonitis - periorchitis and perinatal management. …”
Get full text

Pegilated interferon alpha 2b «Pegaltevir» chronic hepatitis C treatment (randomized clinical trial) by Marina V. Mayevskaya, Ye. N. Bessonova, P. O. Bogomolov, N. I. Geyvandova, K. V. Zhdanov, V. G. Morozov, V. D. Pasechnikov, I. Yu. Khomenko, A. V. Yagoda, V. T. Ivashkin

“…No significant differences between basic and control groups at analysis of paired liver biopsies for fibrosis stage reduction rate, absence of negative changes for fibrosis severity and proportion of patients with fibrosis progression were found. …”
Get full text